Patents Assigned to Calico Life Sciences LLC
  • Anti-PAPP-A antibodies and methods of use thereof
    Patent number: 12157776
    Abstract: Provided herein are anti-PAPP-A antibodies. Also provided are methods of using such antibodies to treat PAPP-A associated disorders such as kidney disease.
    Type: Grant
    Filed: November 14, 2023
    Date of Patent: December 3, 2024
    Assignees: Calico Life Sciences LLC, AbbVie Inc.
    Inventors: Adam Freund, Yuliya Kutskova, Jeffrey R. Barker
  • System and method for inferring protein binding
    Patent number: 11709136
    Abstract: Methods and apparatus for inferring protein binding based on rotational diffusion of a collection of fluorophores.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: July 25, 2023
    Assignee: CALICO LIFE SCIENCES LLC
    Inventors: Andrew Gregory York, Maria Del Mar Ingaramo
  • Prodrug modulators of the integrated stress pathway
    Patent number: 11149043
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: October 19, 2021
    Assignees: Calico Life Sciences LLC, AbbVie Inc.
    Inventors: Michael J. Dart, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, Kathleen Murauski, Marina Pliushchev, Brian S. Brown, Eric Voight, John T. Randolph
  • Fluorescence microscopy system and methods based on stimulated emission
    Patent number: 11009463
    Abstract: Fluorescence imaging based on stimulated emission. In one example a system includes an excitation source (110) that excites fluorescent markers (122) in a sample (120) with an excitation beam (112), a stimulation source (130) that stimulates the excited fluorescent markers (122) to produce stimulated emission (124), and an objective lens (150) that receives the stimulation beam (132) and the stimulated emission (124). The system further includes a phase shifting and attenuation apparatus (200) configured to receive the stimulation beam (132) and the stimulated emission (124) from the objective lens (150), to attenuate the stimulation beam (132), and to induce a relative phase shift between a reference beam (optionally being at least a portion of the stimulation beam) and the stimulated emission, thereby causing constructive interference between the reference beam and the stimulated emission.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: May 18, 2021
    Assignee: CALICO LIFE SCIENCES LLC
    Inventors: Andrew Gregory York, Sanjay Ramesh Varma
  • Modulators of the integrated stress pathway
    Patent number: 10864196
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: December 15, 2020
    Assignees: Calico Life Sciences, LLC, AbbVie Inc.
    Inventors: Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
  • PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20200299246
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    Type: Application
    Filed: June 4, 2020
    Publication date: September 24, 2020
    Applicants: Calico Life Sciences LLC, AbbVie Inc.
    Inventors: Geoff T. Halvorsen, Jennifer M. Frost, Philip R. Kym